ACAD Acadia Pharmaceuticals Inc

Price (delayed)

$53.37

Market cap

$8.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.72

Enterprise value

$8.07B

Sector: Healthcare
Industry: Biotechnology

Highlights

ACAD's gross profit is up by 41% year-on-year and by 7% since the previous quarter
ACAD's revenue is up by 40% YoY and by 7% QoQ
The EPS has decreased by 17% QoQ but it has increased by 2.3% YoY
The quick ratio has declined by 29% year-on-year and by 8% since the previous quarter
The net income has declined by 19% since the previous quarter and by 8% year-on-year

Key stats

What are the main financial stats of ACAD
Market
Shares outstanding
158.98M
Market cap
$8.48B
Enterprise value
$8.07B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.85
Price to sales (P/S)
20.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.26
Earnings
Revenue
$419.07M
EBIT
-$267.27M
EBITDA
-$264.54M
Free cash flow
-$144.18M
Per share
EPS
-$1.72
Free cash flow per share
-$0.91
Book value per share
$4.15
Revenue per share
$2.65
TBVPS
$5.02
Balance sheet
Total assets
$795.66M
Total liabilities
$140.8M
Debt
$45.34M
Equity
$654.87M
Working capital
$638.36M
Liquidity
Debt to equity
0.07
Current ratio
7.95
Quick ratio
7.6
Net debt/EBITDA
1.56
Margins
EBITDA margin
-63.1%
Gross margin
97.4%
Net margin
-63.9%
Operating margin
-66.2%
Efficiency
Return on assets
-34.7%
Return on equity
-40.3%
Return on invested capital
-65.2%
Return on capital employed
-38%
Return on sales
-63.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACAD stock price

How has the Acadia Pharmaceuticals stock price performed over time
Intraday
-0.54%
1 week
-0.37%
1 month
-3.4%
1 year
22.89%
YTD
-0.17%
QTD
-0.17%

Financial performance

How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$419.07M
Gross profit
$408.35M
Operating income
-$277.32M
Net income
-$267.86M
Gross margin
97.4%
Net margin
-63.9%
ACAD's gross profit is up by 41% year-on-year and by 7% since the previous quarter
ACAD's revenue is up by 40% YoY and by 7% QoQ
The operating margin has increased by 23% YoY but it has decreased by 10% QoQ
The net margin has increased by 23% YoY but it has decreased by 12% QoQ

Growth

What is Acadia Pharmaceuticals's growth rate over time

Valuation

What is Acadia Pharmaceuticals stock price valuation
P/E
N/A
P/B
12.85
P/S
20.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.26
The EPS has decreased by 17% QoQ but it has increased by 2.3% YoY
ACAD's price to book (P/B) is 44% higher than its 5-year quarterly average of 8.9 and 25% higher than its last 4 quarters average of 10.3
The company's equity fell by 5% YoY
ACAD's P/S is 99% below its 5-year quarterly average of 3988.5 but 13% above its last 4 quarters average of 17.8
ACAD's revenue is up by 40% YoY and by 7% QoQ

Efficiency

How efficient is Acadia Pharmaceuticals business performance
The ROS has increased by 22% YoY but it has decreased by 12% QoQ
Acadia Pharmaceuticals's return on assets has increased by 21% YoY but it has decreased by 18% QoQ
ACAD's return on invested capital is down by 21% since the previous quarter but it is up by 15% year-on-year
The ROE has contracted by 20% from the previous quarter but it has grown by 20% YoY

Dividends

What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACAD.

Financial health

How did Acadia Pharmaceuticals financials performed over time
The total liabilities has soared by 85% YoY and by 46% QoQ
The quick ratio has declined by 29% year-on-year and by 8% since the previous quarter
The debt is 93% lower than the equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.